BONA
15.1.2024 08:05:25 CET | Business Wire | Press release
Bona, a global, sustainably driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, is announcing the launch of its new lacquer, Bona Mega EVO™. This next generation lacquer offers a new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, the lacquer contributes to healthier working conditions with a lower impact on indoor air quality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240114100435/en/
Announcing Bona Mega EVO™ a next generation lacquer that offers new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, Bona Mega EVO contributes to healthier working conditions with a lower impact on indoor air quality. (Photo: Business Wire)
Bona Mega EVO™ is the next evolution of Bona Mega, which was first introduced in 1996 and offered an industry-first oxygen crosslinking technology and, at the time, was considered a top choice among flooring contractors for use as a one-component topcoat for wood floors in environments requiring medium to light commercial wear resistance. Bona Mega EVO™ is the next generation that incorporates a completely new and significantly faster technology that is unique to Bona. The self crosslinking occurs entirely within the lacquer without the use of any external components, making it a next generation coating.
“When it comes to performance, Bona Mega EVO™ is an advancement in every way. With the new self crosslinking technology, we have merged the top features from Bona Mega and Bona Mega ONE to create an exceptional product. It stands out from the competition due to its consistently high level of performance. Bona Mega EVO™ is the next step for coating medium- to light-commercial areas and domestic wood floors,” said Thomas Hallberg, Director Product Management Professional EMEA/APAC, Bona AB
Bona Mega EVO’s new self crosslinking technology provides a topcoat that dries quickly, remains clear over time, offers excellent sanding ability, and has VOC levels below 3%. It has high filling abilities, low odour, and excellent scratch, wear, and chemical resistance. With Bona Mega EVO’s fast-drying and quick cure time, the floor can be in use more quickly when compared to other one-component lacquers. This also means that the next topcoat layer can be applied much sooner than with traditional polymer technology.
Bona Mega EVO™ guarantees a uniform colouring of the wood floor even without the use of a primer making it possible to use just one product during the whole process. It has a non-yellowing formula with minimal odour during the application process and dissipates rapidly afterwards.
With VOC levels below 3%, Bona Mega EVO™ fulfills the EMICODE® EC1PLUS certification. Bona continues its work to phase out PFAS, of which Bona Mega EVO is no exception, promoting a safer environment.
About Bona
Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. The head office is in Malmö, Sweden, and the company is represented globally across 90 countries through 16 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240114100435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom